FDA Looking at Aricept Study
Posted on: Friday, 17 March 2006, 15:00 CST
The U.S. Food and Drug Administration is examining the results of a study of the drug Aricept, which is used to treat Alzheimer's disease.
The study of 974 patients suffering from dementia, found 11 deaths occurred among patients taking Aricept, while no deaths occurred among those taking the placebo, The New York Times reported Friday.
Susan Bro, a spokeswoman for the FDA, said the agency is examining the results of the study. The agency undertook a review of earlier Aricept studies and found no cause for concern, she said.
However, medical experts say the new study should not be dismissed and it might indicate that Aricept and similar drugs increased the risks of heart disease, the Times said.
No other large trials of the drug have found a similar risk, but that does not mean such a risk is absent, according to Dr. Lon Schneider, a professor of psychiatry, neurology and gerontology at the University of Southern California. Few trials have followed patients for long enough, or included enough patients with serious heart problems, to uncover a mild increase in heart risk, the experts told the Times.
Source: United Press International
Related Articles
- Many Heart Failure Patients Do Not Get Proper Drug Treatments
- Crowded Emergency Clinics Pose Greater Risks For Patients With Heart Attacks
- Studies Indicate Exercise Training Could Provide Some Benefit For Patients With Heart Failure
- Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- Sudafed Beats Singulair in Merck-Funded Allergy Study ; Patients Felt Better Using Pfizer Drug
- Advisers Urge Heart Risk Warning on ADHD Drugs
- US advisers urge heart risk warning on ADHD drugs
- Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia With Darbepoetin Alfa in Patients With Heart Failure to Reduce Mortality and Hospitalization
- Study Finds Celebrex Heart Risk ; Pfizer Doesn't Plan Recall, but Prescription Cut Seen
User Comments (0)

RSS Feeds